“Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s162. doi:10.25251/skin.7.supp.162.